Latest News - Movement Disorders

Wednesday, April 26, 2017 | Movement Disorders, Research and Publications

AAN 2017 Meeting: New Evidence Suggest Parkinson’s Originates in the Gut

Parkinson’s disease may start in the gut and spread to the brain via the vagus nerve, according to a study published in the April 26, 2017, online issue of Neurology®, the medical journal of…

Read the full story

Monday, April 24, 2017 | Movement Disorders, Personnel/Company News, Research and Publications

Elekta: New Data on Stereotactic Neurosurgery Devices Presented at AANS

Elekta's Leksell Gamma Knife® radiosurgery system has been highlighted in more than 15 scientific presentations at the American Association of Neurological Surgeons (AANS) Annual Meeting&…

Read the full story

Wednesday, April 12, 2017 | FDA Approval/Clearance, Movement Disorders, Product Launches and Updates

First Treatment for Tardive Dyskinesia Approved in US

The FDA approved the selective VMAT2 inhibitor Ingrezza (valbenazine, Neurocrine Biosciences), making it the first treatment approved in the US to treat adults with tardive dyskinesia. The efficacy of…

Read the full story

Tuesday, April 04, 2017 | FDA Approval/Clearance, Movement Disorders, Neuromuscular & Immune Disorders, Phase 3/4 Trials

New Therapy for Chorea Associated with Huntington’s Disease Wins FDA Approval

The FDA approved Austedo (deutetrabenazine, Teva Pharmaceuticals) tablets for the treatment of chorea associated with Huntington’s disease (HD), making it just the second product approved for th…

Read the full story

Wednesday, March 22, 2017 | FDA Approval/Clearance, Movement Disorders

Novel Adjunct Agent Approved for Parkinson’s "Off" Periods

The FDA approved Xadago (safinamide, Newron Pharmaceuticals) tablets as an add-on treatment for patients with Parkinson’s disease who are currently taking levodopa/carbidopa and experiencing &ld…

Read the full story

Friday, February 10, 2017 | Movement Disorders, Phase 3/4 Trials

Inhaled Levodopa Impresses in Treating Parkinson’s OFF Periods in Phase 3 Study

New phase 3 data suggests that the experimental inhaled levodopa, CVT-301 (Acorda Therapeutics), may offer significant improvement in motor function in individuals with Parkinson’s disease exper…

Read the full story

Tuesday, November 29, 2016 | Movement Disorders, Research and Publications

Genetic Mutation Tied to Risk of Early Parkinson’s Disease

Aging appears to alter how genetic factors contribute to the development of Parkinson’s disease, according to new research that has identified a gene that may increase risk of early onset P…

Read the full story

Wednesday, October 12, 2016 | Movement Disorders, Research and Publications

Parkinson’s Disease Therapeutic Conference to Spotlight New Research and Potential Therapeutic Targets

The Michael J. Fox Foundation’s 10th annual Parkinson’s Disease Therapeutic Conference, set to take place on October 24 in New York City, will bring together experts and specialists in res…

Read the full story

Friday, October 07, 2016 | FDA Approval/Clearance, Movement Disorders

New DBS System for Parkinson’s Disease, Essential Tremor Approved

The deep brain stimulation market will soon be expanding, as the FDA has approved St. Jude Medical’s Infinity system for the treatment Parkinson’s disease and essential tremor. Also approv…

Read the full story

Thursday, September 22, 2016 | Movement Disorders

WPC 2016: Study Elucidates the Role of Neuroinflammation in Pre-diagnosis Parkinson’s Disease

Anti-inflammatory agents could possibly delay progression to a manifest synucleinopathy in subjects with idiopathic REM sleep behaviour disorder (IRBD), according to new findings presented at the ongo…

Read the full story

Wednesday, September 21, 2016 | Movement Disorders

AANEM 2016: Dysport Found Effective at 2 mL Dilution in Cervical Dystonia

A 12-week study presented at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) suggests that a 2 mL dilution of abobotulinumtoxinA (Dysport, Ipsen) may …

Read the full story